HONG KONG – Underscoring the speed in which China is working to raise its drug regulations to international standard, the World Health Organization (WHO) gave the country's national vaccine regulatory system a stamp of approval in a follow-up assessment since a first inspection was done in 2011.
HONG KONG – Chinese pharmaceutical conglomerate Shanghai Fosun Pharmaceutical Group Co. Ltd. and Sellas Clinicals Holding AG have agreed to terminate an 8-month-old $530 million deal, which covered drug candidates for diabetes and cancer. Fosun said Sellas failed to settle a payment due. Sellas said Fosun declined to renegotiate terms of the deal, proposed because Sellas is seeking to do an initial public offering (IPO) and is realigning.
HONG KONG – Starting this month, Chinese biotech companies will enjoy a 50 percent reduction in value-added tax (VAT) in China, all part of a government plan to standardize taxes across the country.
HONG KONG – Underscoring the speed in which China is working to raise its drug regulations to international standard, the World Health Organization (WHO) gave the country's national vaccine regulatory system a stamp of approval in a follow-up assessment since a first inspection was done in 2011.
HONG KONG – Chinese pharmaceutical conglomerate Shanghai Fosun Pharmaceutical Group Co. Ltd. and Sellas Clinicals Holding AG have agreed to terminate an 8-month-old $530 million deal, which covered drug candidates for diabetes and cancer.
HONG KONG – A Chinese maker of novel oncology, cardiovascular and metabolic drugs is floating shares in Hong Kong next month and has developed a plan to set itself apart from the pack.
HONG KONG – A Japanese technology company has reached an agreement with a UK-based orphan drug developer to co-develop and sell an orphan drug in Japan.
HONG KONG – A Japanese technology company has reached an agreement with a UK-based orphan drug developer to co-develop and sell an orphan drug in Japan. Japan´s Teijin Pharma Ltd. entered an exclusive development and sales agreement with Sigma-Tau Pharmaceuticals Inc. that will allow Teijin to participate in the development of EZN-2279, a therapeutic agent for adenosine deaminase (ADA) deficiency, as well as to distribute the final product in Japan.
HONG KONG – A Chinese maker of novel oncology, cardiovascular and metabolic drugs is floating shares in Hong Kong next month and has developed a plan to set itself apart from the pack.
HONG KONG – A large Chinese conglomerate that rose to fame as a maker of the food additive monosodium glutamate, better known as MSG, has taken definitive steps into the biopharmaceutical space, sealing a deal to buying one of the major hepatitis B vaccine (HBV) suppliers in the country for ¥600 million (US$96 million).
